NL
EN
terug naar home
31-10-2017 BioGeneration Ventures Fund III reaches EUR 82 million in final close 23-10-2017 Pharming meldt voor het merendeel niet-contante uitoefening van warrants en conversie van converteerbare obligaties in aandelen 18-10-2017 BioGeneration Venture’s portfolio onderneming SurgVision gekocht door Bracco Imaging 03-10-2017 Dutch Mellon Medical secures € 6 million for market introduction of major innovation in surgical suture technology: single-handed suturing using the Switch® 02-10-2017 Pharming meldt positieve klinische studiedata met RUCONEST® bij kinderen 26-09-2017 Pharming en de internationale patiëntenkoepel HAEi maken partnership bekend met Inceptua Medicines Access voor wereldwijde toegang van HAE-patiënten tot RUCONEST® 26-07-2017 Pharming maakt publicatie profylactische data RUCONEST® in medisch tijdschrift The Lancet bekend 21-07-2017 Pharming rondt herfinanciering met lening van US$100 miljoen af tegen verbeterde voorwaarden 12-07-2017 MammaPrint® van Agendia aanbevolen in specifieke update van Amerikaanse ASCO borstkankerrichtlijn op basis van gegevens uit de belangrijke MINDACT-studie 06-07-2017 Agendia’s MammaPrint® aanbevolen in belangrijke 2017 update van Internationale St. Gallen Borstkanker Richtlijn 03-04-2017 EUR 12,8 miljoen nieuwe financiering voor biotechonderneming Cristal Therapeutics 14-03-2017 BioGeneration Ventures contributes to Cristal Therapeutics EUR 12.8 million Financing Round 13-02-2017 Europese Commissie breidt marketingvergunning RUCONEST® uit met zelfstandige toediening 08-12-2016 Pharming rondt transactie met Valeant over terugkoop van alle Noord-Amerikaanse rechten RUCONEST® af 07-12-2016 Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform 07-12-2016 Polyganics announces Birmingham Hand Centre efficacy study of nerve conduit NEUROLAC® in finger surgery

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform

Bekijk hier de online versie

   
 
 
 
 
 
 

 

  • Initial goal to determine treatment efficacy of iTeos’ immuno-oncology drug candidates
  • Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates

​Maastricht, The Netherlands and Gosselies, Belgium – December 7th, 2016 – Cristal Therapeutics, a Dutch privately-held life sciences company developing novel nanomedicines against cancer and other diseases and iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced a strategic partnership for the discovery, development and commercialization of optimized immuno anti-cancer drug candidates, using Cristal Therapeutics’ medicinal nanotechnology CriPec® platform.

The initial goal of this partnership is to determine the therapeutic efficacy of targeted drugs using Cristal’s CriPec® application in iTeos’ preclinical models which have been proven to be predictive in combinations of several immune activators - such as IDO1 and TDO2 - with checkpoint inhibitors. iTeos has an option to license Cristal’s proprietary nanotechnology platform to support the development and commercialization of up to three of its immune tumor-targeting programs.

CriPec®, a proprietary nanotechnology platform, consists of tuneable polymers and biodegradable drug linkers that allow for the rational design and straightforward manufacturing of custom-made nanomedicines. Applying the CriPec® platform - drugs entrapped in CriPec® nanoparticles - results in immuno nanomedicines with a superior product profile as compared to the native drug molecule. CriPec® nanoparticles improve the disposition of thousands of drug molecules per particle and allow the controlled release of these molecules specifically at the target site. This results in an improved therapeutic efficacy and tolerability.

Joost Holthuis, Cristal Therapeutics’ CEO, commented: 

“This partnership with iTeos allows us to assess and demonstrate the application of our CriPec® nanoparticles, specifically in the area of novel immuno-oncology therapies. We are focused on applying our nanomedicine platform to several promising oncology indications, some of which will be evaluated for the iTeos’ development pipeline.” 

Michel Detheux, iTeos’ CEO, added: 

“We are very pleased to enter into this partnership with an emerging clinical-stage nanomedicine platform company. Cristal has a strong and experienced management team, and has demonstrated the capability to quickly develop valuable therapeutic programs. We look forward to applying their platform to some of our drug candidates. We believe it has particular potential in the evolving area of causing so-called “cold tumors” – which are less responsive to checkpoint inhibitors - to become susceptible to various immuno-oncology therapies.”

About Cristal Therapeutics

Maastricht, The Netherlands based Cristal Therapeutics, is a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform. CriPec® transforms drugs into polymeric nanoparticles via an innovative process. These nanoparticles provide improved distribution throughout the body. The substantial improvement of the efficacy and safety of the drugs entrapped in CriPec® nanoparticles has been demonstrated in several preclinical disease models. Cristal Therapeutics’ products in development are primarily aimed at treating patients suffering from cancer but offer also opportunities for the treatment of chronic inflammatory diseases. CriPec® docetaxel is the most advanced product candidate, and is under clinical evaluation for the treatment of solid tumors. For more information please visit www.cristaltherapeutics.com.

About iTeos Therapeutics S.A.

Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), is focused on expanding the benefits of immunotherapy for cancer patients. The company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic tumors.  It  has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information please visit www.iteostherapeutics.com

 

 


 
 
 
 

Contacts:

Joost Holthuis, CEO

Cristal Therapeutics

+ 31 43 388 5868

joost.holthuis@cristaltherapeutics.com

 

Michel Detheux, CEO

iTeos therapeutics

+32 71 919 933

michel.detheux@iteostherapeutics.com

 

For iTeos Therapeutics:

Sarah McCabe

Stern Investor Relations, Inc.

+ 1 212 362-1200

sarah@sternir.com

 

Jonathan Birt, Mathew Neal, Hendrik Thys

Consilium Strategic Communications

iteos@consilium-comms.com

+44 2 037 095 700

 

For Cristal Therapeutics:

LifeSpring Life Sciences Communication

Leon Melens

lmelens@lifespring.nl

+31 6 538 16 427


 
 
 

Copyright © 2016 LifeSpring LifeSciences Communication, All rights reserved. 

 

Our address is: 
LifeSpring LifeSciences Communication
Science Park 400
1098 XH Amsterdam
Netherlands

www.lifespring.nl


 
 
 

Science Park 400 Matrix II Building 1098 XH Amsterdam +31 (0)653816427
lmelens@lifespring.nl

  • - Corporate Communications
  • - Healthcare PR
  • - Financial Communications
  • - Content Marketing
  • - Social Media and Online Communications